SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 12/5/2016 10:07:10 AM - Followers: 155 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
SureTrader
IDRA News: Current Report Filing (8-k) 11/28/2016 08:29:23 AM
IDRA News: Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd. Enter Into Exclusive License Agreement for the Worldwide Rights to IM... 11/28/2016 07:00:00 AM
IDRA News: Idera Pharmaceuticals Reports Translational Data Supporting the Mechanism of Action of Intratumoral IMO-2125 from Ongoing Pha... 11/11/2016 03:15:00 PM
IDRA News: Idera to Present at the Stifel 2016 Healthcare Conference 11/10/2016 07:30:00 AM
IDRA News: Idera Pharmaceuticals to Provide Multiple Presentations on Intratumoral IMO-2125 at the 2016 Society for Immunotherapy of Can... 11/09/2016 07:30:00 AM
PostSubject
#2771   Why Idera Pharmaceuticals (IDRA) Could Be Positioned for chmcnfunds 12/05/16 10:07:10 AM
#2770   Looking good $idra Cbdpotential 12/05/16 09:58:11 AM
#2769   $7million of that is listed under R&D. Includes Citrati 12/01/16 09:29:29 AM
#2768   Don't u find a burn rate of 9 slowmover 11/29/16 10:55:05 PM
#2767   Yeh, surprised me. Haven't followed long enough to chmcnfunds 11/29/16 04:26:52 PM
#2766   Nice find thanks. Citrati 11/29/16 02:53:36 PM
#2765   Commentary from Investopedia: chmcnfunds 11/29/16 10:47:36 AM
#2764   We are at a disadvantage to the bots. Citrati 11/29/16 08:55:27 AM
#2763   See that Wedbush reiterated yesterday: chmcnfunds 11/29/16 08:51:26 AM
#2762   What you say makes sense. I just keep chmcnfunds 11/29/16 08:04:20 AM
#2761   Agreed. Sure there was/is strong resistance at $2, Citrati 11/28/16 07:55:30 PM
#2760   Thought it would at least stay above $2.00. chmcnfunds 11/28/16 10:16:04 AM
#2759   noretreat, thanks for posting the PR. Citrati 11/28/16 10:02:46 AM
#2758   Very nice news!! UP Trend 11/28/16 08:48:38 AM
#2757   Got to assume Baker was aware when this chmcnfunds 11/28/16 08:04:41 AM
#2756   The PR: chmcnfunds 11/28/16 07:57:33 AM
#2755   I wonder how far along IDRA was with scottsmith 11/28/16 07:31:53 AM
#2754   BRIEF-Idera Pharmaceuticals and Vivelix Pharmaceuticals, Ltd enter into noretreat 11/28/16 07:28:02 AM
#2753   Nice synopsis. Citrati 11/22/16 01:29:16 AM
#2752   IDRA...Looks like a nice inverse head and shoulders roachmastr33 11/18/16 10:07:55 AM
#2751   Decided to move out of this the other rivervalley 11/18/16 09:49:35 AM
#2750   Thanks, sometimes like to confirm the chart with chmcnfunds 11/17/16 01:22:16 PM
#2749   Thanks for the wishes...much appreciated. Back at ya. Cre8tivmynd 11/17/16 01:21:27 PM
#2748   Wish you well. Citrati 11/17/16 12:51:45 PM
#2747   http://stockcharts.com/h-sc/ui?s=IDRA&p=D&yr=0&mn=3&dy=0&id=p47621597479 I actu Citrati 11/17/16 12:29:16 PM
#2746   What they said about cash is true...but with Cre8tivmynd 11/17/16 12:08:56 PM
#2745   I agree. Was a bit surprised that it chmcnfunds 11/17/16 11:38:01 AM
#2744   As seems to happen when there is a Cre8tivmynd 11/17/16 11:03:49 AM
#2743   No explanations for this stock. Down 10% after chmcnfunds 11/17/16 10:27:45 AM
#2742   Near term milestones from STIFEL 2016 HEALTHCARE CONFERENCE chmcnfunds 11/16/16 03:32:14 PM
#2741   Webcast link: chmcnfunds 11/16/16 03:14:06 PM
#2740   Wedbush outperform: chmcnfunds 11/14/16 08:30:38 AM
#2739   "Immunological analysis of the biopsy taken from the Cbdpotential 11/13/16 07:36:13 PM
#2738   Thanks. Here is the correlation. Citrati 11/13/16 04:24:03 PM
#2737   We'll see how it does over the next rivervalley 11/11/16 05:12:10 PM
#2736   With the 2 board positions I'm sure the chmcnfunds 11/11/16 04:17:43 PM
#2735   Yeah I'm still in. I can't see selling rivervalley 11/11/16 04:11:11 PM
#2734   They did -- sell the news. Good news chmcnfunds 11/11/16 04:08:23 PM
#2733   Let's go IDRA $2 is calling? lol rivervalley 11/11/16 03:53:11 PM
#2732   data looks great, extremely encouraging wow binchey 11/11/16 03:37:31 PM
#2731   Just saw the pr come out just wasn't rivervalley 11/11/16 03:27:26 PM
#2730   From the just released PR: chmcnfunds 11/11/16 03:24:27 PM
#2729   I've been looking at their site, is their rivervalley 11/11/16 03:19:55 PM
#2728   New Slides: chmcnfunds 11/11/16 03:17:42 PM
#2727   Interesting that despite the presentation at 3:15 today, chmcnfunds 11/11/16 02:31:04 PM
#2726   Sure looking better so far today headed to chmcnfunds 11/11/16 10:02:54 AM
#2725   I start smiling when pps passes my buy rivervalley 11/10/16 05:17:57 PM
#2724   This is a tough crowd. Citrati 11/10/16 03:39:28 PM
#2723   IDRA my top performer today which is great. rivervalley 11/09/16 04:21:20 PM
#2722   If there's one thing that I've learned over Cre8tivmynd 11/09/16 03:30:39 PM
PostSubject